A Double-Blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Patients With Intermittent Explosive Disorder

摘要: Background: Intermittent explosive disorder (IED) is a of impulsive aggression that affects as many 7.3% the U.S. population during some period life. Since central serotonergic (5-HT) system dysfunction related to aggressive behavior, pharmacologic enhancement 5-HT activity should reduce behavior in individuals with IED. Method: A double-blind, randomized, placebo-controlled trial selective uptake inhibitor fluoxetine was conducted 100 IED (research diagnostic criteria) and current histories behavior. The primary efficacy measure score from Overt Aggression Scale-Modified (OAS-M) for Outpatient Use. Secondary measures included irritability OAS-M Clinical Global Impressions-Improvement scale (CGI-I) score. study took place between July 1990 1999. Results: Fluoxetine treatment resulted sustained reduction aggression, scores, apparent early week 2 (p < .01 p .001 at endpoint). also superior placebo proportion responders on CGI-I .001). Closer examination data revealed full or partial remission behaviors, reflected by criteria IED, occurred 46% fluoxetine-treated subjects. did not exert an antidepressant antianxiety effect, its effects were influenced presence symptoms depression anxiety. Couclusion: has clear antiaggressive effect However, while fluoxetine's appear robust, they lead less than 50% subjects treated fluoxetine.